The stock of MorphoSys AG (NASDAQ:MOR) last traded at $3.93, down -0.25% from the previous session.
Data from the available sources indicates that MorphoSys AG (NASDAQ:MOR) is covered by 6 analysts. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $32.00 and a low of $4.13, we find $6.48. Given the previous closing price of $3.94, this indicates a potential upside of 64.47 percent. MOR stock price is now -21.11% away from the 50-day moving average and -30.43% away from the 200-day moving average. The market capitalization of the company currently stands at $519.39M.
In total, 2 analysts have assigned it a hold rating, and 2 have given it a buy rating. Brokers who have rated the stock have averaged $11.01 as their price target over the next twelve months.
, while ‘Deutsche Bank’ rates the stock as ‘Sell’.
There have been several recent changes in the stakes of large investors in MOR stock. A new stake in MorphoSys AG shares was purchased by OPALEYE MANAGEMENT INC. during the first quarter worth $476,000. ALLY BRIDGE GROUP (NY) LLC invested $373,000 in shares of MOR during the first quarter. In the first quarter, ENDURANT CAPITAL MANAGEMENT LP acquired a new stake in MorphoSys AG valued at approximately $268,000. CITADEL ADVISORS LLC acquired a new stake in MOR for approximately $79,000. In total, there are 29 active investors with 2.10% ownership of the company’s stock.
With an opening price of $3.8600 on Tuesday morning, MorphoSys AG (NASDAQ: MOR) set off the trading day. During the past 12 months, MorphoSys AG has had a low of $3.79 and a high of $11.06. The fifty day moving average price for MOR is $4.9816 and a two-hundred day moving average price translates $5.6491 for the stock.
The latest earnings results from MorphoSys AG (NASDAQ: MOR) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$1.7, missing analysts’ expectations of -$0.27 by -1.43. This compares to $0.18 EPS in the same period last year. The company reported revenue of $63.26 million for the quarter, compared to $46.07 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 37.31 percent. For the current quarter, analysts expect MOR to generate $67.62M in revenue.
MorphoSys AG(MOR) Company Profile
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer’s diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.